D&D Pharmatech (KRX: 347850)
Who is buying D&D Pharmatech?
Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net bought ₩5.7bn ($4M) of D&D Pharmatech, the 71st largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩10.4bn ($8M) and retail investors net bought ₩3.7bn ($3M) over the same window. Foreigners were net buyers on 14 of the 20 sessions.
Foreign investors hold 10.57% of D&D Pharmatech's listed shares (KRX ownership data as of Oct 16, 2026), up from 10.36% twenty sessions earlier and 1.02% a year ago.
The stock closed at ₩38,100 on Oct 16, 2026: -17.26% over 20 sessions, -58.50% year-to-date, -9.54% over one year. The 52-week range is ₩34,500 – ₩116,600.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-16 | ₩38,100 | +₩2.3bn | +₩1.5bn | ₩-3.7bn |
| 2026-10-15 | ₩35,400 | +₩2.8bn | +₩0.3bn | ₩-3.1bn |
| 2026-10-14 | ₩37,800 | +₩1.0bn | ₩-0.4bn | ₩-0.7bn |
| 2026-10-13 | ₩37,600 | +₩4.2bn | ₩-0.9bn | ₩-3.5bn |
| 2026-10-12 | ₩40,150 | +₩1.0bn | ₩-1.0bn | +₩0.1bn |
| 2026-10-08 | ₩42,850 | ₩-0.9bn | ₩-2.6bn | +₩4.3bn |
| 2026-10-07 | ₩46,100 | ₩-9.0bn | +₩0.8bn | +₩8.1bn |
| 2026-10-06 | ₩47,550 | ₩-3.7bn | +₩1.2bn | +₩2.1bn |
| 2026-10-02 | ₩43,000 | ₩-3.6bn | ₩-0.7bn | +₩4.4bn |
| 2026-10-01 | ₩45,250 | +₩0.8bn | +₩3.7bn | ₩-4.7bn |
| 2026-09-30 | ₩41,850 | +₩1.7bn | ₩-0.9bn | ₩-0.9bn |
| 2026-09-29 | ₩41,950 | +₩2.8bn | ₩-1.5bn | ₩-1.0bn |
| 2026-09-28 | ₩43,200 | ₩-5.5bn | +₩0.5bn | +₩3.8bn |
| 2026-09-23 | ₩44,500 | +₩2.7bn | ₩-0.3bn | ₩-2.5bn |
| 2026-09-22 | ₩42,800 | +₩3.1bn | ₩-5.1bn | +₩1.8bn |
| 2026-09-21 | ₩44,600 | +₩2.9bn | ₩-3.3bn | +₩0.4bn |
| 2026-09-18 | ₩45,300 | +₩0.5bn | ₩-1.3bn | +₩0.8bn |
| 2026-09-17 | ₩46,050 | ₩-1.2bn | ₩-0.3bn | +₩1.6bn |
| 2026-09-16 | ₩46,050 | +₩2.7bn | ₩-0.1bn | ₩-2.3bn |
| 2026-09-15 | ₩46,650 | +₩1.3bn | +₩0.0bn | ₩-1.4bn |
| 2026-09-14 | ₩46,050 | +₩1.3bn | ₩-1.0bn | ₩-0.3bn |
| 2026-09-11 | ₩47,550 | +₩3.5bn | ₩-3.6bn | +₩0.6bn |
| 2026-09-10 | ₩48,800 | +₩3.2bn | ₩-3.1bn | ₩-0.1bn |
| 2026-09-09 | ₩49,500 | +₩3.7bn | ₩-6.6bn | +₩3.1bn |
| 2026-09-08 | ₩49,300 | +₩1.9bn | ₩-3.2bn | +₩1.3bn |
| 2026-09-07 | ₩49,700 | +₩1.4bn | ₩-2.8bn | +₩1.3bn |
| 2026-09-04 | ₩49,200 | +₩1.1bn | ₩-3.4bn | +₩2.4bn |
| 2026-09-03 | ₩48,500 | +₩4.5bn | ₩-4.4bn | ₩-0.1bn |
| 2026-09-02 | ₩49,050 | +₩7.0bn | ₩-7.3bn | +₩0.1bn |
| 2026-09-01 | ₩51,800 | +₩4.3bn | ₩-5.7bn | +₩1.2bn |
| 2026-08-31 | ₩53,500 | +₩0.3bn | ₩-5.1bn | +₩4.9bn |
| 2026-08-28 | ₩55,600 | ₩-0.9bn | ₩-0.4bn | +₩1.7bn |
| 2026-08-27 | ₩56,300 | +₩7.2bn | ₩-7.5bn | +₩0.3bn |
| 2026-08-26 | ₩56,300 | ₩-1.8bn | ₩-4.9bn | +₩6.9bn |
| 2026-08-25 | ₩56,200 | ₩-0.8bn | +₩0.5bn | +₩0.3bn |
| 2026-08-24 | ₩57,300 | +₩7.2bn | +₩5.1bn | ₩-12.5bn |
| 2026-08-21 | ₩53,300 | ₩-10.9bn | ₩-10.1bn | +₩20.3bn |
| 2026-08-20 | ₩57,800 | ₩-2.2bn | ₩-1.4bn | +₩3.5bn |
| 2026-08-19 | ₩58,100 | +₩4.8bn | +₩0.1bn | ₩-4.3bn |
| 2026-08-18 | ₩57,800 | +₩8.6bn | ₩-5.5bn | ₩-1.5bn |
| 2026-08-14 | ₩61,400 | +₩1.9bn | ₩-5.6bn | +₩3.5bn |
| 2026-08-13 | ₩61,700 | +₩11.7bn | ₩-8.1bn | ₩-3.7bn |
| 2026-08-12 | ₩60,500 | +₩6.2bn | ₩-6.4bn | +₩0.0bn |
| 2026-08-11 | ₩60,900 | ₩-17.0bn | ₩-14.4bn | +₩31.7bn |
| 2026-08-10 | ₩65,700 | +₩7.1bn | +₩17.7bn | ₩-24.6bn |
| 2026-08-07 | ₩57,500 | +₩1.5bn | +₩3.1bn | ₩-4.9bn |
| 2026-08-06 | ₩55,700 | ₩-0.0bn | +₩3.1bn | ₩-4.1bn |
| 2026-08-05 | ₩53,100 | ₩-38.3bn | +₩4.8bn | +₩34.5bn |
| 2026-08-04 | ₩64,800 | ₩-7.4bn | +₩16.0bn | ₩-8.4bn |
| 2026-08-03 | ₩56,700 | ₩-0.0bn | +₩4.6bn | ₩-4.3bn |
| 2026-07-31 | ₩50,400 | +₩3.8bn | ₩-0.3bn | ₩-3.4bn |
| 2026-07-30 | ₩45,700 | +₩5.3bn | ₩-1.4bn | ₩-3.7bn |
| 2026-07-29 | ₩48,650 | +₩18.3bn | ₩-4.4bn | ₩-13.4bn |
| 2026-07-28 | ₩55,500 | +₩5.9bn | ₩-5.6bn | ₩-0.2bn |
| 2026-07-27 | ₩59,000 | ₩-8.1bn | +₩0.4bn | +₩7.8bn |
| 2026-07-24 | ₩59,600 | +₩0.6bn | +₩0.8bn | ₩-1.3bn |
| 2026-07-23 | ₩64,000 | +₩5.0bn | ₩-0.1bn | ₩-4.9bn |
| 2026-07-22 | ₩59,000 | ₩-1.2bn | ₩-8.6bn | +₩9.5bn |
| 2026-07-21 | ₩61,000 | +₩5.5bn | ₩-12.4bn | +₩6.7bn |
| 2026-07-20 | ₩64,300 | +₩6.0bn | ₩-5.7bn | +₩0.4bn |
| 2026-07-16 | ₩68,700 | ₩-19.8bn | ₩-8.5bn | +₩28.4bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩2.3bn | +$2M | +₩1.5bn | ₩-3.7bn |
| 5 days | +₩11.3bn | +$8M | ₩-0.4bn | ₩-10.9bn |
| 20 days | +₩5.7bn | +$4M | ₩-10.4bn | +₩3.7bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying D&D Pharmatech stock?
Over the last 5 sessions foreign investors net bought ₩11.3bn ($8M) of D&D Pharmatech; over 60 sessions they net bought ₩55.4bn ($41M); since Jan 1, 2026 they net sold ₩1.0bn ($1M). Over 20 sessions the stock is the 71st largest foreign net purchase among 1828 KOSDAQ stocks.
How much of D&D Pharmatech do foreign investors own?
Foreign investors own 10.57% of D&D Pharmatech's shares as of Oct 16, 2026, versus 1.02% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩10.4bn ($8M) and retail investors net bought ₩3.7bn ($3M) of D&D Pharmatech. Foreign buying is being met mainly by institutional selling.
Is D&D Pharmatech listed on KOSPI or KOSDAQ?
D&D Pharmatech (디앤디파마텍) trades on KOSDAQ under KRX code 347850 in the Biotech & Pharma group, with a market capitalization of ₩2T ($1.3B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2024 | ₩11bn ($8M) | – | -₩25bn (-$19M) | -₩29bn (-$22M) |
| 2025 | ₩4bn ($3M) | -62.40% | -₩34bn (-$25M) | -₩24bn (-$18M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.